<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Screening for osteoporosis in postmenopausal women and men</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Screening for osteoporosis in postmenopausal women and men</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Screening for osteoporosis in postmenopausal women and men</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine W Yu, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clifford J Rosen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth E Schmader, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 14, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Osteoporosis is a common disease that is characterized by low bone mass, microarchitectural disruption, and skeletal fragility, resulting in an increased risk of fracture. The goal of screening is to identify persons at increased risk of sustaining a low-trauma fracture who would benefit from intervention to minimize that risk.</p><p>Approaches to bone mineral density (BMD) screening vary from country to country, in part due to cost and questions regarding the efficacy of a broad population screening policy. The issues surrounding screening for osteoporosis in older adults are reviewed here. Controversies surrounding screening for osteoporosis in premenopausal women are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Osteoporosis is characterized by low bone mass, microarchitectural disruption, and increased skeletal fragility, resulting in decreased bone strength and increased risk of fracture. Fragility fractures are defined as fractures that occur with low or minimal trauma, such as a fracture resulting from a fall from standing height. The most common sites of fragility fracture are the spine (vertebral compression fractures), hip, and wrist. Fragility fractures also occur at the humerus, rib, and pelvis. Fractures at certain skeletal locations, including the skull, cervical spine, hands, feet, and ankles, are not considered to be fragility fractures. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/2052.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men", section on 'Diagnosis of osteoporosis'</a>.)</p><p>The World Health Organization (WHO) has also defined osteoporosis based on dual-energy x-ray absorptiometry (DXA) measurements  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>). The relative risk of fracture increases as bone mineral density (BMD) decreases. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The burden of suffering associated with osteoporosis is related to the increased incidence of fractures in individuals with low bone mass and microarchitectural deterioration.</p><p>An estimated nine million osteoporotic fractures occurred worldwide in 2000 [<a href="#rid1">1</a>]. The incidence of hip fractures increases exponentially with age, although the increase begins approximately 10 years later in males than females  (<a class="graphic graphic_figure graphicRef58577" href="/z/d/graphic/58577.html" rel="external">figure 1</a>) [<a href="#rid2">2</a>]. In systematic reviews, the worldwide annual hip fracture rate in women ranged from &lt;100 to nearly 600 per 100,000 and vertebral fracture rate from &lt;100 to almost 1400 per 100,000, depending on the region [<a href="#rid3">3,4</a>]. The highest rates of hip fracture occurred in Scandinavian countries [<a href="#rid3">3</a>], whereas the highest rates of vertebral fracture occurred in South Korea and the United States [<a href="#rid4">4</a>]. As the global population ages, the estimated annual number of hip fractures is expected to double between 2018 and 2050 [<a href="#rid5">5</a>]. The prevalence of vertebral or hip fracture in older men is approximately one-third that in women (5 to 6 percent versus 16 to 18 percent), and Colles' fracture one-sixth as common (2.5 versus 16 percent) [<a href="#rid6">6</a>].</p><p>Based on bone mineral density (BMD) data from the National Health and Nutrition Examination Survey (NHANES), the prevalence of osteoporosis was 12.6 percent among adults aged 50 years and over in the United States in 2017 to 2018, with a higher prevalence in women (19.6 percent) than in men (4.4 percent) [<a href="#rid7">7</a>]. By the age of 85 years, approximately 70 percent of women and over 30 percent of men will have a femoral neck T-score at or below -2.5  (<a class="graphic graphic_figure graphicRef122913" href="/z/d/graphic/122913.html" rel="external">figure 2</a>) [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H4"><span class="h1">FRACTURE RISK ASSESSMENT</span><span class="headingEndMark"> — </span>The goal of osteoporosis screening is to identify persons at increased risk of sustaining a low-trauma fracture who would benefit from intervention to minimize that risk [<a href="#rid10">10</a>]. Screening for fracture risk involves appropriate history and physical examination to assess for risk factors and measurement of bone mineral density (BMD). (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a>.)</p><p class="headingAnchor" id="H7950392"><span class="h2">Risk factor assessment</span><span class="headingEndMark"> — </span>We recommend assessing risk factors for fracture in all adults, especially postmenopausal women, men over 50 years, and in any individual who experiences a fragility or low-trauma fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>).</p><p>Most fractures occur in individuals who do not have osteoporosis by dual-energy x-ray absorptiometry (DXA) criteria  (<a class="graphic graphic_table graphicRef74190" href="/z/d/graphic/74190.html" rel="external">table 1</a>). Although individuals with osteoporosis are at higher relative risk of fracture, there are more fractures in patients with low bone mass (T-score between -1.0 and -2.5) because there are so many more patients in this category. Therefore, assessment of risk factors that are independent of BMD is important for fracture prediction. Validated risk factors that are independent of BMD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Previous fracture</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term glucocorticoid therapy</p><p class="bulletIndent1"><span class="glyph">●</span>Low body weight (less than 58 kg [127 lb])</p><p class="bulletIndent1"><span class="glyph">●</span>Parental history of hip fracture</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Excess alcohol intake</p><p class="bulletIndent1"><span class="glyph">●</span>Race/ethnicity (higher risk with White than with Black, Hispanic, or Asian ancestry)</p><p></p><p>The most robust non-BMD risk factors are age and previous low-trauma<strong> </strong>fracture. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a>.)</p><p>Most of these risk factors are easily discernible from a routine history and physical examination; taken together, they are highly predictive of low bone density [<a href="#rid11">11</a>] and future hip fracture, even in the absence of BMD measurement [<a href="#rid12">12</a>]. Although clinical risk factors are predictive of bone density and fracture risk, they may not be as useful for predicting response to therapy for osteoporosis [<a href="#rid13">13</a>].</p><p>Biochemical markers that reflect the overall rates of bone resorption and formation are available clinically and have been used extensively in research to help understand the pathogenesis of osteoporosis and responses to therapy. The mean values of these markers are generally higher in patients with osteoporosis than in matched normal subjects, but there is substantial overlap [<a href="#rid14">14-17</a>]. Measurement of these markers is not helpful in deciding for or against bone density measurements. However, markers can provide information about fracture risk beyond that available from measurements of BMD and could conceivably influence a decision for or against pharmacologic intervention [<a href="#rid18">18,19</a>]. Current evidence is insufficient to recommend the routine use of bone markers to identify individuals who would benefit from pharmacologic interventions to reduce fracture risk. (See  <a class="medical medical_review" href="/z/d/html/2041.html" rel="external">"Use of biochemical markers of bone turnover in osteoporosis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Risk factor screening instruments</span><span class="headingEndMark"> — </span>Several osteoporosis risk assessment instruments have been developed to improve the selection of individuals for measurement of BMD [<a href="#rid20">20-23</a>]. The extent to which each tool has been validated in other cohorts is variable [<a href="#rid24">24</a>]. The Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a>) has been evaluated in the most cohorts [<a href="#rid25">25</a>].</p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a> was developed to estimate the 10-year probability of hip fracture or major osteoporotic fractures combined (hip, spine, shoulder, or wrist) for an untreated woman or man using easily obtainable clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>) with or without information on BMD. The technical aspects of FRAX are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Fracture risk assessment tool'</a>.)</p><p>When combined with country-specific economic analyses, FRAX can provide guidance for both BMD testing (assessment threshold) and treatment (intervention threshold). In the United States, where access to DXA is relatively widespread, BMD assessment thresholds have been recommended by the US Preventive Services Task Force (USPSTF) (see <a class="local">'Recommendations by expert groups'</a> below). In countries with limited access to DXA, the FRAX algorithm can potentially be used to identify individuals in whom measurement of BMD would influence management decisions. As an example, measurement of BMD may be indicated in those with an intermediate fracture probability, in whom the selective addition of BMD testing may result in intervention [<a href="#rid26">26</a>]. In contrast, in those with high fracture probability, intervention may be justified without BMD measurement. Country-specific economic analyses are required to validate these assessment thresholds, ie, the fracture probability at which BMD testing is cost effective.</p><p>The use of the FRAX algorithm to define intervention thresholds is reviewed separately, including potential limitations. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Clinical application of fracture risk assessment'</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Bone mineral density</span><span class="headingEndMark"> — </span>Bone mineral density (BMD) measurements are used in conjunction with fracture risk assessment for osteoporosis screening [<a href="#rid27">27</a>]. Low BMD is associated with increased risk of fracture, regardless of the technique used for measurement. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Methods of measurement of BMD'</a>.)</p><p class="headingAnchor" id="H1541782683"><span class="h3">Candidates for BMD testing</span><span class="headingEndMark"> — </span>There are several strategies for incorporating bone mineral density (BMD) measurements into osteoporosis surveillance programs [<a href="#rid28">28</a>]. These include screening all individuals over a certain age (when fracture risk increases), screening only those individuals over a certain age with clinical risk factors for fracture, or screening those with clinical risk factors who are close to an intervention threshold and in whom the selective addition of BMD testing may result in intervention.</p><p class="bulletIndent1"><span class="glyph">●</span>We suggest BMD testing (DXA) in all women 65 years of age and older and in postmenopausal women younger than 65 years of age with clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>). These recommendations are based upon the findings of an increased incidence of fracture that occurs in conjunction with low BMD after age 65 years and clinical trial data demonstrating a reduction in fractures when these women are treated, in addition to clinical trial evidence showing a reduction in hip fractures in women identified for treatment through a community-based osteoporosis screening algorithm [<a href="#rid29">29,30</a>]. (See <a class="local">'Evidence'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not perform routine testing in men based solely on age. Instead, we suggest targeted BMD testing in men with clinical manifestations of low bone mass, such as radiographic osteopenia, history of low-trauma fractures, or loss of more than 1.5 inches in height, as well as in those with risk factors for fracture, such as long-term glucocorticoid therapy, androgen deprivation therapy for prostate cancer, hypogonadism, frailty, primary hyperparathyroidism, or gastrointestinal malabsorption. (See  <a class="medical medical_review" href="/z/d/html/2049.html" rel="external">"Etiology of osteoporosis in men", section on 'Etiology'</a>.)</p><p></p><p class="bulletIndent1">Measuring BMD in men solely because they are above a certain age is controversial. Some groups, such as the Bone Health and Osteoporosis Foundation (BHOF; formerly the National Osteoporosis Foundation [NOF]), International Society for Clinical Densitometry (ISCD), and the Endocrine Society recommend BMD testing for all men older than 70 years (and in men 50 to 70 years when risk factors are present) (see <a class="local">'Recommendations by expert groups'</a> below). This recommendation is supported by data suggesting that total hip bone density predicts fractures as well or better in males than in females [<a href="#rid31">31,32</a>]. Other data, however, do not support routine BMD screening for men based solely on age [<a href="#rid33">33,34</a>]. In general, fracture data from clinical trials of osteoporosis therapies are quite limited in men, so there is less certainty that treatment of men who are identified by routine screening will benefit from therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMD screening recommendations for premenopausal women are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis", section on 'Screening'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Dual-energy x-ray absorptiometry</span><span class="headingEndMark"> — </span>DXA is the most widely used method for measuring BMD because it gives very precise measurements at clinically relevant skeletal sites (ie, those with major clinical consequences when a fracture occurs). The major disadvantages of DXA are that the machine is large (not portable) and expensive and that it uses ionizing radiation, albeit in a very low dose. (See  <a class="medical medical_review" href="/z/d/html/2056.html" rel="external">"Overview of dual-energy x-ray absorptiometry"</a>.)</p><p>Many studies have demonstrated that low bone density (DXA) at any site can predict osteoporotic fracture, although hip measurements are superior to spine in predicting hip as well as overall osteoporotic fracture. DXA and fracture prediction are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Dual-energy x-ray absorptiometry (DXA)'</a>.)</p><p class="headingAnchor" id="H1860701660"><span class="h3">Other techniques not routinely used for screening</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative computed tomography (QCT)</strong> – QCT measures volumetric bone density of the spine and hip and can analyze cortical and trabecular bone separately. This method is quite useful in clinical research and may be used in individual patients to follow therapeutic responses to therapy, where large changes may be observed. However, it is not recommended for screening, largely because the application of T-scores to predict the risk of fracture has not been validated with QCT. In addition, this method is more costly and results in greater exposure to radiation than DXA. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Quantitative computed tomography'</a>.)</p><p></p><p class="bulletIndent1">New algorithms have been developed to repurpose CT scans obtained for other clinical reasons as a bone density screening tool [<a href="#rid35">35</a>]; however, these algorithms have yet to be validated on a large scale for osteoporosis screening [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quantitative heel ultrasound</strong> –<strong> </strong>Although ultrasound has some utility for fracture prediction, we continue to recommend DXA for screening purposes because of the inability to apply ultrasound to current diagnostic and treatment standards and to monitor response to therapy [<a href="#rid37">37</a>]. In regions without access to DXA, however, peripheral measurements using a validated technique (such as ultrasound) for fracture risk assessment is acceptable. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Quantitative ultrasonography (QUS)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other peripheral measurements</strong> – Because of the relatively high cost and lack of portability of DXA, other techniques to measure peripheral sites have been developed. In addition to ultrasound, these include peripheral DXA (pDXA), radiograph absorptiometry, and peripheral QCT (pQCT) of the heel, radius, or hand [<a href="#rid27">27</a>]. The World Health Organization (WHO) criteria for the diagnosis of osteoporosis are based upon BMD measured by DXA and, therefore, do not apply to these other technologies. However, these technologies can be used to predict fracture. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Methods of measurement of BMD'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Skeletal site to measure</span><span class="headingEndMark"> — </span>For screening site of measurement, we obtain DXA of hip and spine. Spinal osteophytes are common in aging adults, which interferes with the assessment of BMD at this site. In this setting, measurement of hip BMD alone could be sufficient. Some experts have a somewhat different approach, using the hip as the preferred site for measuring BMD, regardless of age [<a href="#rid26">26,38</a>].</p><p>Although overall fracture risk can be predicted by measurement or estimation of BMD at many skeletal sites [<a href="#rid39">39,40</a>], the risk for fracture at a particular skeletal site is best estimated by measuring BMD at that skeletal site [<a href="#rid38">38,41-43</a>]. As an example, hip BMD is superior to BMD measured at other skeletal sites in predicting hip fracture. Therefore, since hip fracture is often associated with significant morbidity and mortality compared with other fractures, DXA of the hip is generally regarded as the best site for diagnosis of osteoporosis.</p><p>In early menopause, however, there is greater BMD loss at the spine than the hip, and therefore, lumbar spine measurement may be helpful in this setting. If pharmacologic therapy is planned, measurement of lumbar spine BMD is also useful because the lumbar spine is often considered the best skeletal site for monitoring response to therapy. The lumbar spine has improved precision and can detect responses to therapy earlier than hip BMD. In the presence of degenerative changes of the spine, BMD can be monitored at another skeletal site, such as the hip or radius, although the sensitivity for detecting changes at these locations is lower. (See  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Dual-energy x-ray absorptiometry (DXA)'</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Skeletal site to measure'</a>.)</p><p>Measurements from different sites (spine, hip, forearm) are often discordant with regard to the WHO diagnostic classification [<a href="#rid42">42,44</a>]. Most experts suggest that when measurements of different skeletal sites are performed, the diagnosis of osteoporosis is based upon the lowest T-score for BMD assessed at one of these sites [<a href="#rid45">45</a>]. This strategy substantially increases the number of individuals categorized as having osteoporosis.</p><p class="headingAnchor" id="H14"><span class="h2">Recommendations by expert groups</span><span class="headingEndMark"> — </span>In the United States and Canada, most society guidelines recommend BMD assessment in postmenopausal women aged 65 years and older regardless of risk factors, men aged ≥65 to 70 years, and younger adults with history of fragility fracture or clinical risk factors for fracture [<a href="#rid33">33,46-55</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p>There is no universal agreement about BMD testing in older men. The USPSTF found insufficient evidence to make a recommendation for screening older men [<a href="#rid51">51</a>]. Other groups, such as the BHOF, the ISCD, the Endocrine Society, the American College of Preventive Medicine, and the American College of Physicians (ACP) recommend BMD testing for all men older than 70 years, and the Canadian Osteoporosis Society recommends BMD testing for all men older than 65 years.</p><p>BMD screening recommendations for individuals younger than 65 years also vary. The USPSTF recommends BMD screening in women younger than 65 years who are at increased risk for osteoporosis based on a clinical risk assessment tool [<a href="#rid51">51</a>]. One approach is to obtain a BMD in women younger than 65 years whose 10-year risk of major osteoporotic fracture (calculated without DXA) is greater than that of a 65-year-old White American or European woman who has no additional risk factors for fracture. In the United States, this threshold (using FRAX) is 8.4 percent. Although this approach to bone density screening may have merit, the selected threshold (8.4 percent) has not been subject to cost-effectiveness analysis nor validated in any patient population [<a href="#rid56">56,57</a>].</p><p>The BHOF, ISCD, the Endocrine Society, and the Canadian Osteoporosis Society recommend testing in individuals 50 years and older with any clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>) [<a href="#rid49">49,52,58,59</a>], whereas the ACP recommends measurement of BMD in men who are at increased risk for osteoporosis (including men &gt;70 years of age) and are candidates for drug therapy [<a href="#rid60">60</a>].</p><p>In contrast, some European groups recommend BMD screening based upon risk stratification, ie, the decision to measure BMD is based upon age-specific fracture probability thresholds calculated using FRAX (without BMD information) or other risk assessment tool [<a href="#rid28">28,50</a>]. Only individuals with a fracture probability near an intervention threshold, in whom the selective addition of BMD testing may result in intervention, are referred for BMD testing [<a href="#rid28">28,61-63</a>].</p><p class="headingAnchor" id="H15"><span class="h1">EFFECTIVENESS OF OSTEOPOROSIS SCREENING</span></p><p class="headingAnchor" id="H3794152825"><span class="h2">Evidence</span><span class="headingEndMark"> — </span>There are a few trials that directly evaluate the effectiveness of osteoporosis screening [<a href="#rid29">29,30,64-66</a>]. There was a reduction in hip fractures in the screening compared with control group in one of the trials [<a href="#rid29">29</a>], but not in others [<a href="#rid64">64-66</a>]. In these trials, determining the relative effectiveness of screening depends upon the quality of the bone mineral density (BMD) measurements and the risk factor analysis, the ability of the clinician to prescribe appropriate treatment, and the compliance of the patient. </p><p>In a meta-analysis of the three population-based randomized controlled trials that evaluated screening for high fracture risk in postmenopausal women using bone densitometry and provided recommendations for subsequent osteoporosis treatment, there was a reduction in hip fractures (2.2 versus 2.7 percent in the control group [hazard ratio (HR) 0.80, 95% CI 0.71-0.91]), major osteoporotic fractures (7.8 versus 8.4 percent [HR 0.91, 95% CI 0.84-0.98]), and in osteoporotic fractures (11.2 versus 11.7 percent [HR 0.95, 95% CI 0.89-1.00]) [<a href="#rid30">30</a>]. There was no difference in all-cause mortality, a secondary outcome. All three trials used the Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a>) in combination with bone densitometry for screening, and 11 to 18 percent of participants in the intervention group initiated osteoporosis medication after screening.</p><p>Other estimates of the fracture prevention benefits of screening and intervention are largely based upon trials of bisphosphonates that enrolled postmenopausal women who were at high risk for fracture. The fracture benefits noted are not applicable to a screening program, because patients were not identified for participation in the trials by screening the general population [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3768403645"><span class="h2">Cost effectiveness</span><span class="headingEndMark"> — </span>The results of cost-effectiveness analyses of screening and pharmacologic therapy for the primary or secondary prevention of osteoporotic fractures have not been uniform. Cost effectiveness varies from country to country but generally increases the later in life that screening and treatment occur, with history of prior vertebral fracture, with history of falls, and with decreasing T-score values [<a href="#rid67">67-72</a>].</p><p>A community-based osteoporosis screening algorithm was determined to be highly cost effective in the United Kingdom, with cost savings due to reduction of osteoporotic fractures [<a href="#rid73">73</a>]. Differences in cost effectiveness among countries are related to differences in health care costs and fracture risks. Use of less expensive pharmacologic interventions, such as generic drugs, would further decrease costs.</p><p class="headingAnchor" id="H19"><span class="h1">FOLLOW-UP TO SCREENING</span></p><p class="headingAnchor" id="H2698029870"><span class="h2">General principles</span><span class="headingEndMark"> — </span>In conjunction with osteoporosis screening, individuals require counseling regarding fracture prevention, including lifestyle modification, fall prevention, and possibly pharmacologic intervention.</p><p class="bulletIndent1"><span class="glyph">●</span>All individuals should be counseled about risk factor reduction (see <a class="local">'Fracture risk assessment'</a> above), especially with regard to smoking cessation, limiting alcohol intake, and participating in regular weightbearing and muscle-strengthening exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adults with low bone mass should be advised to consume at least 1200 mg of calcium per day (total diet plus supplement). Adequate vitamin D intake (diet and supplement) is also essential, but there are conflicting guidelines concerning the ideal/optimal supplement, with some guidelines recommending 600 international units as a minimum and others recommending 1000 international units. (See  <a class="medical medical_review" href="/z/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial laboratory evaluation in individuals with low bone mass (bone mineral density [BMD] T-score below -1.0) should include standard biochemical and hematologic profiles, 25-hydroxyvitamin D, and possibly a measure of urine calcium (spot fasting or 24 hour) excretion. Further recommendations regarding initial evaluation of low bone mass are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The World Health Organization (WHO) BMD definitions for osteoporosis and low bone mass are diagnostic thresholds rather than intervention thresholds. Pharmacologic intervention thresholds to prevent fracture should be based upon the absolute risk of fracture, using a combination of BMD and clinical risk factors  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>). Intervention thresholds are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Repeat BMD measurements</span><span class="headingEndMark"> — </span>Our approach in individuals without osteoporosis at baseline measurement and who are not candidates for pharmacologic therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of low bone mass (T-score -2.00 to -2.49) at any site <strong>or</strong> risk factors that may cause ongoing bone loss (eg, glucocorticoid use, hyperparathyroidism), we perform follow-up measurements approximately every two years, as long as risk factors persist. (See  <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">"Primary hyperparathyroidism: Management", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of low bone mass (T-score -1.50 to -1.99) at any site, and with no risk factors for accelerated bone loss, we will typically perform a follow-up dual-energy x-ray absorptiometry (DXA) in three to five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of normal or slightly low bone mass (T-score -1.01 to -1.49), with no risk factors for accelerated bone loss and with low absolute fracture risk, we will typically perform a follow-up DXA in 10 to 15 years. In our practice, we also recommend periodic redetermination of Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a>) 10-year probability of fracture every five years, with the further recommendation to perform a follow-up DXA earlier if the absolute fracture risk is close to the treatment threshold (ie, ≥3 percent for hip fracture, ≥20 percent for major osteoporotic fracture).</p><p></p><p>Any properly installed and validated DXA instrument is appropriate for initial BMD measurement. However, to the extent possible, it is preferable that all subsequent BMD studies on an individual patient should be performed on the same DXA instrument as the baseline study.</p><p>Follow-up testing for individuals whose baseline BMD shows osteoporosis (T-score &lt;-2.5) and for patients receiving osteoporosis treatment is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Monitoring the response to therapy'</a>.)</p><p>Data regarding the frequency of follow-up BMD testing when the initial screening test does not show osteoporosis are limited [<a href="#rid74">74</a>]. The goal of follow-up testing is to detect low bone density before a major fracture occurs. However, whether rate of BMD loss is an independent risk factor for fracture is uncertain [<a href="#rid75">75-79</a>]. In a retrospective cohort study using a database of all clinical BMD results from Manitoba, Canada, 146 women (mean age 65 years) sustained one or more osteoporotic fractures after the second BMD test [<a href="#rid76">76</a>]. Compared with women who remained fracture free, women who fractured were older, had lower baseline (T-scores lumbar spine -1.0 versus -1.6 and femoral neck -1.2 versus -1.7, respectively) and final BMD, and a higher prevalence of other risk factors for fracture (ie, glucocorticoid use). However, the annualized percentage change in BMD did not differ in women who did and did not sustain major osteoporotic fractures.</p><p>In contrast, the Framingham Osteoporosis study, a population-based cohort study of 800 older adults (mean age at baseline BMD test 74.8 years) who had two BMD tests and were followed for a median of 9.6 years, showed that the change in BMD of the femoral neck was associated with hip and major osteoporotic fracture [<a href="#rid80">80</a>]. However, the change in BMD over a four-year interval provided little additional clinically valuable information beyond the baseline BMD.</p><p>Similarly, in the Study of Osteoporotic Fractures (SOF), a repeat BMD measurement performed a mean of eight years after the initial measurement did not improve the overall predictive value of hip, spine, or non-spine fracture risk in 4124 community-dwelling women 65 years and older (mean age 72 years) [<a href="#rid75">75</a>]. The mean initial T-score was -1.37. In a subsequent analysis from SOF, 4957 women (67 years and older) who did not have osteoporosis at baseline testing were followed for up to 15 years [<a href="#rid81">81</a>]. The interval for 10 percent of participants to make the transition from normal BMD or osteopenia at baseline to osteoporosis (defined as a T-score -2.50 or lower) was estimated. For women with normal (T-score -1.0 or better) or slightly low (T-score -1.01 to -1.49) bone mass at baseline, the interval between baseline testing and the development of osteoporosis was approximately 17 years. For women with moderately low (T-score -1.50 to -1.99) or low (T-score -2.00 to -2.49) bone mass at baseline, the interval was 4.7 and 1.1 years, respectively. These data suggest that healthy women 65 years of age and older who have a screening bone density study and are found to have normal bone density or only slightly low bone mass may not require repeat testing for 17 years, whereas women found to have moderately low or low bone mass at baseline require follow-up bone density testing within one to five years. Note, however, that treatment thresholds (for example, based on absolute fracture risk) may differ from diagnostic thresholds (based on T-score of -2.5 or lower), and therefore, it is possible that some women who do not have osteoporosis but who have moderate or high absolute fracture risk may benefit from more frequent bone density testing to identify the proper timing for intervention. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Patient selection'</a>.)</p><p>These results are not applicable to women with osteoporosis (T-scores below -2.5) at baseline, women already receiving osteoporosis treatment, or women younger than 65 years of age at time of first bone density screening. Women younger than 65 years of age with clinical risk factors for fracture  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>) may require more frequent monitoring of bone density, depending upon risk factors.</p><p>Repeat BMD measurements may be most valuable for individual patients on therapy or to document stability of bone density in untreated patients with underlying clinical factors that might lead to accelerated bone loss. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women", section on 'Monitoring response to initial pharmacotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men", section on 'Monitoring the response to therapy'</a>.)</p><p class="headingAnchor" id="H1906265661"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105492.html" rel="external">"Society guideline links: Osteoporosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116407.html" rel="external">"Society guideline links: Clinical densitometry"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15482.html" rel="external">"Patient education: Osteoporosis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15536.html" rel="external">"Patient education: Calcium and vitamin D for bone health (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2160.html" rel="external">"Patient education: Osteoporosis prevention and treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2169.html" rel="external">"Patient education: Calcium and vitamin D for bone health (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial fracture risk assessment</strong> – The goal of osteoporosis screening is to identify persons at increased risk of sustaining a low-trauma fracture who would benefit from intervention to minimize that risk. Screening for fracture risk involves appropriate history and physical examination to assess for risk factors  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>) and measurement of bone mineral density (BMD). (See <a class="local">'Fracture risk assessment'</a> above and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment"</a>.)</p><p></p><p class="bulletIndent1">Several osteoporosis risk assessment instruments have been developed to improve the selection of individuals for measurement of BMD. The Fracture Risk Assessment Tool (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a>) has been evaluated in the most cohorts. (See <a class="local">'Risk factor screening instruments'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BMD: Women ≥65 years</strong> – We suggest BMD assessment in all women 65 years of age and older (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Candidates for BMD testing'</a> above and <a class="local">'Evidence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BMD: Women &lt;65 years</strong> – We suggest BMD assessment in postmenopausal women less than 65 years if one or more risk factors are present  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Candidates for BMD testing'</a> above and <a class="local">'Evidence'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BMD: Men</strong> – We suggest targeted BMD testing in men rather than routine testing based solely on age (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Some expert groups advocate for screening men based on age alone (eg, 70 years or above). (See <a class="local">'Candidates for BMD testing'</a> above and <a class="local">'Recommendations by expert groups'</a> above.)</p><p></p><p class="bulletIndent2">We measure BMD in men who have clinical manifestations of low bone mass, such as radiographic osteopenia, history of low-trauma fractures, or loss of more than 1.5 inches in height, as well as in men with risk factors for fracture, such as long-term glucocorticoid therapy, androgen deprivation therapy for prostate cancer, hypogonadism, frailty, primary hyperparathyroidism, hyperthyroidism, or gastrointestinal malabsorption  (<a class="graphic graphic_table graphicRef76445" href="/z/d/graphic/76445.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BMD: Skeletal site to measure</strong> – We measure BMD of the hip and spine using DXA. However, measurement of the hip alone could be sufficient in older individuals. (See <a class="local">'Dual-energy x-ray absorptiometry'</a> above and <a class="local">'Skeletal site to measure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up to screening</strong> – Individuals require counseling regarding fracture prevention, including lifestyle modification, fall prevention, and possibly pharmacologic intervention. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/z/d/html/2035.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeat BMD measurements</strong> – Repeat BMD measurements may be most valuable for individual patients on therapy or with underlying clinical risk factors that might lead to accelerated bone loss. (See <a class="local">'Repeat BMD measurements'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T-score -2.00 to -2.49 at any site or risk factors</strong> – In adults with low bone mass (T-score -2.00 to -2.49) at any site or who have risk factors for ongoing bone loss (eg, glucocorticoid use, hyperparathyroidism), we suggest follow-up measurements (approximately every two years), as long as the risk factor persists (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T-score -1.50 to -1.99 at any site, no risk factors</strong> – In women 65 years of age and older at baseline screening, with low bone mass (T-score -1.50 to -1.99) at any site, and with no risk factors for accelerated bone loss, we suggest a follow-up DXA in three to five years (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T-score -1.01 to -1.49 at any site, no risk factors</strong> – In women 65 years of age and older with normal or slightly low bone mass (T-score -1.01 to -1.49) at baseline measurement and no risk factors for accelerated bone loss and with low absolute fracture risk, we suggest a follow-up DXA in 10 to 15 years (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In our practice, we also recommend periodic redetermination of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrax.shef.ac.uk%2FFRAX%2F&amp;token=fepc1OvGmj9Xs8wyYhQbk%2FGTz8LmEiwfW6Fd9ALhrJ9NMFdekTO7s3ssPifAcpum&amp;TOPIC_ID=2046" target="_blank">FRAX</a> 10-year probability of fracture every five years, with the further recommendation to perform a follow-up DXA earlier if the absolute fracture risk is close to the treatment threshold (ie, ≥3 percent for hip fracture, ≥20 percent for major osteoporotic fracture).</p><p></p><p class="headingAnchor" id="H3746817933"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Kleerekoper, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726.</a></li><li><a class="nounderline abstract_t">Farmer ME, White LR, Brody JA, Bailey KR. Race and sex differences in hip fracture incidence. Am J Public Health 1984; 74:1374.</a></li><li><a class="nounderline abstract_t">Kanis JA, Odén A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012; 23:2239.</a></li><li><a class="nounderline abstract_t">Ballane G, Cauley JA, Luckey MM, El-Hajj Fuleihan G. Worldwide prevalence and incidence of osteoporotic vertebral fractures. Osteoporos Int 2017; 28:1531.</a></li><li><a class="nounderline abstract_t">Sing CW, Lin TC, Bartholomew S, et al. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality. J Bone Miner Res 2023; 38:1064.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7:1005.</a></li><li class="breakAll">Osteoporosis or Low Bone Mass in Older Adults: United States, 2017–2018; NCHS Data Brief, March 2021. Available at: www.cdc.gov/nchs/products/databriefs/db405.htm (Accessed on October 18, 2022).</li><li><a class="nounderline abstract_t">Trajanoska K, Schoufour JD, de Jonge EAL, et al. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study. Bone 2018; 114:116.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd. How many women have osteoporosis now? J Bone Miner Res 1995; 10:175.</a></li><li><a class="nounderline abstract_t">Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med 2024.</a></li><li><a class="nounderline abstract_t">Johansson H, Oden A, Johnell O, et al. Optimization of BMD measurements to identify high risk groups for treatment--a test analysis. J Bone Miner Res 2004; 19:906.</a></li><li><a class="nounderline abstract_t">Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.</a></li><li><a class="nounderline abstract_t">Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19:764.</a></li><li><a class="nounderline abstract_t">Bettica P, Taylor AK, Talbot J, et al. Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J Clin Endocrinol Metab 1996; 81:542.</a></li><li><a class="nounderline abstract_t">Seibel MJ, Woitge H, Scheidt-Nave C, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994; 9:1433.</a></li><li><a class="nounderline abstract_t">McLaren AM, Hordon LD, Bird HA, Robins SP. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992; 51:648.</a></li><li><a class="nounderline abstract_t">Seibel MJ, Cosman F, Shen V, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res 1993; 8:881.</a></li><li><a class="nounderline abstract_t">Christiansen C, Riis BJ, Rødbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; 1:1105.</a></li><li><a class="nounderline abstract_t">Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303:961.</a></li><li><a class="nounderline abstract_t">Cadarette SM, Jaglal SB, Kreiger N, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ 2000; 162:1289.</a></li><li><a class="nounderline abstract_t">Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286:57.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012; 344:e3427.</a></li><li class="breakAll">https://www.garvan.org.au/promotions/bone-fracture-risk/calculator/ (Accessed on August 01, 2018).</li><li><a class="nounderline abstract_t">Dagan N, Cohen-Stavi C, Leventer-Roberts M, Balicer RD. External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study. BMJ 2017; 356:i6755.</a></li><li><a class="nounderline abstract_t">Marques A, Ferreira RJ, Santos E, et al. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74:1958.</a></li><li><a class="nounderline abstract_t">Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399.</a></li><li><a class="nounderline abstract_t">Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164.</a></li><li><a class="nounderline abstract_t">Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16:229.</a></li><li><a class="nounderline abstract_t">Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 2018; 391:741.</a></li><li><a class="nounderline abstract_t">Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 2020; 31:251.</a></li><li><a class="nounderline abstract_t">Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 2006; 21:1550.</a></li><li><a class="nounderline abstract_t">Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007; 22:211.</a></li><li><a class="nounderline abstract_t">Viswanathan M, Reddy S, Berkman N, et al. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 319:2532.</a></li><li><a class="nounderline abstract_t">Drake MT, Murad MH, Mauck KF, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:1861.</a></li><li><a class="nounderline abstract_t">Adams AL, Fischer H, Kopperdahl DL, et al. Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). J Bone Miner Res 2018; 33:1291.</a></li><li><a class="nounderline abstract_t">Gausden EB, Nwachukwu BU, Schreiber JJ, et al. Opportunistic Use of CT Imaging for Osteoporosis Screening and Bone Density Assessment: A Qualitative Systematic Review. J Bone Joint Surg Am 2017; 99:1580.</a></li><li><a class="nounderline abstract_t">Bouxsein M, Parker RA, Greenspan SL. Forearm bone mineral densitometry cannot be used to monitor improvements in hip and spine bone density after 2.5 years of alendronate therapy. Bone 1998; 23:S312.</a></li><li><a class="nounderline abstract_t">Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.</a></li><li><a class="nounderline abstract_t">Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7:633.</a></li><li><a class="nounderline abstract_t">Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815.</a></li><li><a class="nounderline abstract_t">Blake GM, Fogelman I. Peripheral or central densitometry: does it matter which technique we use? J Clin Densitom 2001; 4:83.</a></li><li><a class="nounderline abstract_t">Eastell R, Wahner HW, O'Fallon WM, et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 1989; 83:168.</a></li><li><a class="nounderline abstract_t">Melton LJ 3rd, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227.</a></li><li><a class="nounderline abstract_t">Davis JW, Ross PD, Wasnich RD. Evidence for both generalized and regional low bone mass among elderly women. J Bone Miner Res 1994; 9:305.</a></li><li><a class="nounderline abstract_t">Kanis JA, Johnell O, Oden A, et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 2006; 17:527.</a></li><li><a class="nounderline abstract_t">Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA 2002; 288:1889.</a></li><li><a class="nounderline abstract_t">Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94:646.</a></li><li class="breakAll">http://www.aace.com/pub/pdf/guidelines/OsteoGuidelines2010.pdf (Accessed on January 10, 2011).</li><li><a class="nounderline abstract_t">Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.</a></li><li><a class="nounderline abstract_t">Leslie WD, Schousboe JT. A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr Osteoporos Rep 2011; 9:129.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Curry SJ, Krist AH, et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA 2018; 319:2521.</a></li><li><a class="nounderline abstract_t">LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2022; 33:2049.</a></li><li><a class="nounderline abstract_t">Lim LS, Hoeksema LJ, Sherin K, ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009; 36:366.</a></li><li><a class="nounderline abstract_t">Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin N. 129. Osteoporosis. Obstet Gynecol 2012; 120:718. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 2021; 28:973.</a></li><li class="breakAll">https://www.uspreventiveservicestaskforce.org/Page/Name/us-preventive-services-task-force-opportunities-for-public-comment (Accessed on November 28, 2017).</li><li><a class="nounderline abstract_t">Crandall CJ, Ensrud KE. Osteoporosis Screening in Younger Postmenopausal Women. JAMA 2020; 323:367.</a></li><li><a class="nounderline abstract_t">Baim S, Binkley N, Bilezikian JP, et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11:75.</a></li><li><a class="nounderline abstract_t">Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802.</a></li><li><a class="nounderline abstract_t">Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:680.</a></li><li><a class="nounderline abstract_t">Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62:105.</a></li><li class="breakAll">National Osteoporosis Guideline Group (NOGG). http://www.shef.ac.uk/NOGG/index.html (Accessed on June 29, 2011).</li><li><a class="nounderline abstract_t">Rabar S, Lau R, O'Flynn N, et al. Risk assessment of fragility fractures: summary of NICE guidance. BMJ 2012; 345:e3698.</a></li><li><a class="nounderline abstract_t">Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int 2010; 21:561.</a></li><li><a class="nounderline abstract_t">Rubin KH, Rothmann MJ, Holmberg T, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 2018; 29:567.</a></li><li><a class="nounderline abstract_t">Merlijn T, Swart KM, van Schoor NM, et al. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial. J Bone Miner Res 2019; 34:1993.</a></li><li><a class="nounderline abstract_t">Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int 1996; 6:265.</a></li><li><a class="nounderline abstract_t">Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006; 17:996.</a></li><li><a class="nounderline abstract_t">Johnell O, Jönsson B, Jönsson L, Black D. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 2003; 21:305.</a></li><li><a class="nounderline abstract_t">Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18:1047.</a></li><li><a class="nounderline abstract_t">Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152:621.</a></li><li><a class="nounderline abstract_t">Ito K. Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls. JAMA Netw Open 2020; 3:e2027584.</a></li><li><a class="nounderline abstract_t">Turner DA, Khioe RFS, Shepstone L, et al. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res 2018; 33:845.</a></li><li><a class="nounderline abstract_t">Leslie WD, Crandall CJ. Serial Bone Density Measurement for Osteoporosis Screening. JAMA 2021; 326:1622.</a></li><li><a class="nounderline abstract_t">Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:155.</a></li><li><a class="nounderline abstract_t">Leslie WD, Morin SN, Lix LM, Manitoba Bone Density Program. Rate of bone density change does not enhance fracture prediction in routine clinical practice. J Clin Endocrinol Metab 2012; 97:1211.</a></li><li><a class="nounderline abstract_t">Berger C, Langsetmo L, Joseph L, et al. Association between change in BMD and fragility fracture in women and men. J Bone Miner Res 2009; 24:361.</a></li><li><a class="nounderline abstract_t">Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 2005; 20:1195.</a></li><li><a class="nounderline abstract_t">Ahmed LA, Emaus N, Berntsen GK, et al. Bone loss and the risk of non-vertebral fractures in women and men: the Tromsø study. Osteoporos Int 2010; 21:1503.</a></li><li><a class="nounderline abstract_t">Berry SD, Samelson EJ, Pencina MJ, et al. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture. JAMA 2013; 310:1256.</a></li><li><a class="nounderline abstract_t">Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366:225.</a></li></ol></div><div id="topicVersionRevision">Topic 2046 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983459" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An estimate of the worldwide prevalence and disability associated with osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6507690" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Race and sex differences in hip fracture incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419370" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A systematic review of hip fracture incidence and probability of fracture worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28168409" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Worldwide prevalence and incidence of osteoporotic vertebral fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37118993" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414493" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Perspective. How many women have osteoporosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414493" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Perspective. How many women have osteoporosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29885926" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7754796" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : How many women have osteoporosis now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38190715" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15190881" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Optimization of BMD measurements to identify high risk groups for treatment--a test analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862179" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068500" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636265" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7817828" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616331" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8352070" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883442" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prediction of rapid bone loss in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1954420" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10813010" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434827" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22619194" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22619194" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28104610" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26248637" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266020" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : European guidance for the diagnosis and management of osteoporosis in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014886" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical practice. Screening for osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618996" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Requirements for DXA for the management of osteoporosis in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254858" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838551" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16995809" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17059373" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predictors of non-spine fracture in elderly men: the MrOS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946734" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466344" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29665068" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926388" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Opportunistic Use of CT Imaging for Osteoporosis Screening and Bone Density Assessment: A Qualitative Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Forearm bone mineral densitometry cannot be used to monitor improvements in hip and spine bone density after 2.5 years of alendronate therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709929" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414481" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Axial and appendicular bone density predict fractures in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735756" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477301" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Peripheral or central densitometry: does it matter which technique we use?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2910906" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256660" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term fracture prediction by bone mineral assessed at different skeletal sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8191922" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evidence for both generalized and regional low bone mass among elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16402164" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The use of multiple sites for the diagnosis of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12377088" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical use of bone densitometry: scientific review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8506892" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8506892" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940232" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21655931" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29946735" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35478046" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The clinician's guide to prevention and treatment of osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19285200" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914492" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : ACOG Practice Bulletin N. 129. Osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448749" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448749" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917384" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Osteoporosis Screening in Younger Postmenopausal Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18442754" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22675062" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Osteoporosis in men: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458281" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135323" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135323" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22875946" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Risk assessment of fragility fractures: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19565176" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29218381" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31220365" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883114" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16570118" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12627984" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17333449" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479027" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33258906" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470854" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34698797" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Serial Bone Density Measurement for Osteoporosis Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242316" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22278427" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Rate of bone density change does not enhance fracture prediction in routine clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18847328" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Association between change in BMD and fragility fracture in women and men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940372" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Femoral neck bone loss predicts fracture risk independent of baseline BMD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936871" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bone loss and the risk of non-vertebral fractures in women and men: the Tromsøstudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065012" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22256806" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bone-density testing interval and transition to osteoporosis in older women.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
